Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines

Vaccine

Volumn 29, Issue 41, 2011, Pages 7163-7172

  Wei, Hung Ju ^a   Chang, Weihau ^b   Lin, Shih Chang ^a   Liu, Wen Chun ^a   Chang, Ding Kao ^b   Chong, Pele ^c   Wu, Suh Chin ^a,c  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b INSTITUTE OF CHEMISTRY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Fabrication; Influenza; M2 fusion; Virus like particle

Indexed keywords

BACULOVIRUS VECTOR; ENHANCED GREEN FLUORESCENT PROTEIN; FLAGELLIN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; OLIGOMER; PROFILIN; PROTEIN HA; PROTEIN M1; PROTEIN M2; PROTEIN NA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL MATURATION; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA SEQUENCE; DRUG CONJUGATION; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; SEQUENCE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; VIRUS LIKE AGENT; VIRUS RECOMBINANT; WESTERN BLOTTING; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIOTECHNOLOGY; CELL LINE; DENDRITIC CELLS; FLAGELLIN; GENETIC ENGINEERING; GREEN FLUORESCENT PROTEINS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PROFILINS; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; STAINING AND LABELING; TECHNOLOGY, PHARMACEUTICAL; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, VIROSOME; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 80052485617     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.077     Document Type: Article

References (37)

1. Horimoto T., Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 2005, 3:591-600.
2. Scheiffele P., Roth M.G., Simons K. Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain. EMBO J 1997, 16(18):5501-5508.
3. Zhang J., Pekosz A., Lamb R.A. Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins. J Virol 2000, 74(10):4634-4644.
4. Gomez-Puertas P., Albo C., Perez-Pastrana E., Vivo A., Portela A. Influenza virus matrix protein is the major driving force in virus budding. J Virol 2000, 74:11538-11547.
5. Haynes J.R. Influenza virus-like particle vaccines. Expert Rev Vaccines 2009, 8(4):435-445.
6. Enami M., Enami K. Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein. J Virol 1996, 70(10):6653-6657.
7. Ali A., Avalos R.T., Pomimaskin E., Nayak D.P. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J Virol 2000, 74:8709-8719.
8. Jin H., Leser G.P., Zhang J., Lamb R.A. Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J 1997, 16:1236-1247.
9. Iwatsuki-Horimoto K., Horimoto T., Noda T., Kiso M., Maeda J., Watanabe S., et al. The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J Virol 2006, 80:5233-5240.
10. McCown M.F., Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol 2006, 80:8178-8189.
11. Chen B.J., Leser G.P., Jackson D., Lamb R.A. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J Virol 2008, 82(20):10059-10070.
12. Wang D., Harmon A., Jin J., Francis D.H., Christopher-Hennings J., Nelson E., et al. The lack of an inherent membrane targeting signal is responsible for the failure of the matrix (M1) protein of influenza a virus to bud into virus-like-particles. J Virol 2010, 84(9):4673-4681.
13. Wu C.Y., Yeh Y.C., Yang Y.C., Chou C., Liu M.T., Wu H.S., et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 2010, 5(3):e9784.
14. Kost T.A., Condreay J.P., Jarvis D.L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 2005, 23:567-575.
15. Quan F.S., Huang C., Compans R.W., Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007, 81(7):3514-3524.
16. Quan F.S., Steinhauer D., Huang C., Ross T.M., Compans R.W., Kang S.M. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008, 26(26):3352-3361.
17. Wang B.Z., Quan F.S., Kang S.M., Bozja J., Skountzou I., Compans R.W. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008, 82(23):11813-11823.
18. Quan F.S., Yoo D.G., Song J.M., Clements J.D., Compans R.W., Kang S.M. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol 2009, 83(9):4489-4497.
19. Quan F.S., Vunnava A., Compans R.W., Kang S.M. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One 2010, 5(2):e9161.
20. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23:5751-5759.
21. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(19):3871-3878.
22. Pushko P., Tumpey T.M., Van Hoeven N., Belser J.A., Robinson R., Nathan M., et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007, 25(21):4283-4290.
23. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole D.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3(1):e1501.
24. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26:5393-5399.
25. Crevar C.J., Ross T.M. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J 2008, 5:131.
26. Kang S.M., Yoo D.G., Lipatov A.S., Song J.M., Davis C.T., Quan F.S., et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009, 4(3):e4667.
27. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009, 83(11):5726-5734.
28. Ross T.M., Mahmood K., Crevar C.J., Schneider-Ohrum K., Heaton P.M., Bright R.A. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 2009, 4(6):e6032.
29. Latham T., Galarza J.M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001, 75:6154-6165.
30. Jarvis D.L., Kawar Z.S., Hollister J.R. Engineering N-glycosylation pathways in the baculvirus-insect cell system. Curr Opin Biotechnol 1998, 9(5):528-533.
31. Hollister J., Grabenhorst E., Nimtz M., Conradt H., Jarvis D.L. Engineering the protein N-glycosylation pathway in insect cells for production of biantennary, complex N-glycans. Biochemistry 2002, 41(50):15093-15104.
32. Hollister J., Conradt H., Jarvis D.L. Evidence for a sialic acid salvaging pathway in lepidopteran insect cells. Glycobiology 2003, 13(6):487-495.
33. Lakadamyali M., Rust M.J., Babcock H.P., Zhuang X. Visualizing infection of individual influenza viruses. Proc Natl Acad Sci USA 2003, 100(16):9280-9285.
34. Rust M.J., Lakadamyali M., Zhang F., Zhuang X. Assembly of endocytic machinery around individual influenza viruses during viral entry. Nat Struct Mol Biol 2004, 11(6):567-573.
35. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531-569.
36. Shinya K., Fujii Y., Ito H., Ito T., Kawaoka Y. Characterization of a neuraminidase-deficient influenza A virus as a potential gene delivery vector and a live vaccine. J Virol 2004, 78(6):3083-3088.
37. Song L., Zhang Y., Yun N.E., Poussard A.L., Smith J.N., Smith J.K., et al. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 2009, 27(42):5875-5884.